Doxorubicin Cardiotoxicity Prevention via SGLT2 Inhibitor Empagliflozin in Preclinical Murine and Translational Models

Explore doxorubicin-induced cardiotoxicity mechanisms and metabolic rescue via SGLT2 inhibitor empagliflozin in preclinical models of heart failure.

EXECUTIVE SUMMARY

Key Scientific Takeaways

Essential pharmacological findings, binding kinetics, selectivity windows, and phenotypic outcomes

  • 1
    Anthracycline-induced cardiotoxicity restricts the clinical utility of doxorubicin in curative oncology regimens.
  • 2
    Pharmacological inhibition of the sodium-glucose cotransporter 2 (SGLT2, encoded by SLC5A2) in the S1/S2 segments of the renal proximal convoluted tubule prevents the reabsorption of filtered glucose [1].
  • 3
    In Wistar rats exposed to cumulative doses of doxorubicin, the expression of key ketone-utilizing enzymes BDH1 and succinyl-CoA:3-ketoacid CoA transferase (SCOT, encoded by OXCT1) is upregulated up to twofold following.
  • 4
    Reduced oxidative stress suppresses calcium/calmodulin-dependent protein kinase II (CaMKII) auto-phosphorylation at Thr286/Thr287, preventing pathological phosphorylation of RyR2 at Ser2814 that causes diastolic calcium leakage [6].
  • 5
    Co-administration of empagliflozin was investigated in immunocompetent murine oncology models, including syngeneic 4T1 mammary carcinoma and B16-F10 melanoma [1][5].
Check the Doxorubicin (Adriamycin) Hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
EXTRACELLULAR MEMBRANE CYTOPLASM NUCLEUS MOA PATHWAY — Doxorubicin (Adriamycin) P=Phospho | ->=Activate | -|=Inhibit Doxorubicin Ki 1.3 nM β-OHB MCT1 MITOCHONDRIA ROS mPTP Caspase-3 Ca 2+ SERCA2a BDH1 SCOT Acetyl-CoA ATM P Akt Ser473 P TOP2B p53 PGC-1α NRF-1
Proposed Mechanism of Action and Downstream Signaling Pathway Cascade of Doxorubicin (Adriamycin) and Empagliflozin Co-treatment.

A multi-compartment signaling pathway diagram detailing the renal-cardiac-hepatic axis. The renal section outlines SGLT2 inhibition driving glycosuria, shifting the glucagon/insulin ratio to trigger hepatic CPT-1A activation and β-OHB generation. The cardiomyocyte compartment displays doxorubicin-induced TOP2B damage and PDH blockade, contrasted with parallel β-OHB uptake via MCT1/2, enzymatic processing through BDH1 and SCOT/OXCT1 into acetyl-CoA, preservation of the ATP/ADP pool, inhibition of mPTP opening, and restoration of SERCA2a and titin phosphorylation.

Topoisomerase IIβ Trapping and Mitochondrial Energetic Arrest in Anthracycline Cardiotoxicity

Anthracycline-induced cardiotoxicity restricts the clinical utility of doxorubicin in curative oncology regimens. While the antineoplastic action of doxorubicin depends on topoisomerase IIα poisoning in rapidly dividing malignant cells, myocardial toxicity is mediated by topoisomerase IIβ (TOP2B) in quiescent cardiomyocytes [1]. Doxorubicin intercalates into genomic DNA and stabilizes a ternary cleavage intermediate with TOP2B, generating persistent double-strand breaks that trigger ATM/ATR kinase cascades and p53-mediated transcriptional silencing [2]. This genomic stress directly downregulates peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) and nuclear respiratory factor-1 (NRF-1), terminating the transcription of nuclear-encoded mitochondrial subunits [1][3].

As summarized in Table 1, the pathophysiological parameters separating doxorubicin-induced damage from normal metabolic baseline illustrate this catastrophic bioenergetic failure. In H9C2 rat cardiac myoblasts, doxorubicin treatment causes an immediate collapse of spare respiratory capacity, while resting fatty acid β-oxidation drops markedly [2]. The resulting blockade of palmitate oxidation promotes intracellular accumulation of toxic acylcarnitines and unesterified free fatty acids. Electrons leaking from compromised Complex I and Complex III react with molecular oxygen to produce high fluxes of superoxide (O₂^{\bullet-}), generating hydrogen peroxide (H₂O₂) and hydroxyl radicals (^{\bulletOH}). This oxidative cascade causes extensive peroxidation of cardiolipin, a phospholipid essential for retaining cytochrome c within the inner mitochondrial membrane [3]. Cytochrome c detachment triggers downstream activation of caspase-9 and caspase-3, alongside opening of the mitochondrial permeability transition pore (mPTP). Consequently, calcium-dependent excitation-contraction coupling fails due to oxidative impairment of the sarcoplasmic/endoplasmic reticulum calcium ATPase 2a (SERCA2a) and oxidation of ryanodine receptor 2 (RyR2), precipitating diastolic arrest.

Systemic Ketogenesis Induction via Renal SGLT2 Blockade by Empagliflozin

Pharmacological inhibition of the sodium-glucose cotransporter 2 (SGLT2, encoded by SLC5A2) in the S1/S2 segments of the renal proximal convoluted tubule prevents the reabsorption of filtered glucose [1]. Empagliflozin exhibits high selectivity for SGLT2 over SGLT1, with an inhibitory constant Ki of 1.3 nM versus 1100 nM, promoting targeted glycosuria without causing off-target gastrointestinal toxicity [1]. In male C57BL/6J mice, daily oral administration of empagliflozin at 10 to 30 mg/kg decreases circulating blood glucose concentrations by 20% to 35%, which triggers an adaptive reduction in pancreatic β-cell insulin secretion and a concomitant elevation in plasma glucagon [2][4].

This altered circulating insulin-to-glucagon ratio stimulates hepatic lipolysis and redirects long-chain fatty acids into hepatocytes [4]. The reduction in malonyl-CoA relieves allosteric inhibition of carnitine palmitoyltransferase-1A (CPT-1A), accelerating fatty acyl-CoA translocation across the mitochondrial membrane for subsequent β-oxidation [1]. Within hepatic mitochondria, excess acetyl-CoA is converted via 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2) into acetoacetate, which is then reduced to β-hydroxybutyrate (β-OHB) by β-hydroxybutyrate dehydrogenase 1 (BDH1). Systemic plasma levels of β-OHB rise from baseline values of 0.1–0.2 mM to steady-state concentrations between 0.6 and 1.2 mM [2]. This sustained, physiological ketonemia operates independently of systemic acidosis. Instead of relying on glucose or long-chain fatty acids—both of which exhibit compromised metabolic pathways in the presence of anthracyclines—the injured myocardium is supplied with a circulating, energetically dense alternative fuel capable of rapid extraction.

Metabolic Rescue via Cardiomyocyte Ketone Oxidation and BDH1/SCOT Upregulation

Cardiomyocytes import circulating β-OHB through monocarboxylate transporters, primarily MCT1 (encoded by SLC16A1) and MCT2 (SLC16A7), driven by a proton symport mechanism [2]. In Wistar rats exposed to cumulative doses of doxorubicin, the expression of key ketone-utilizing enzymes BDH1 and succinyl-CoA:3-ketoacid CoA transferase (SCOT, encoded by OXCT1) is upregulated up to twofold following empagliflozin administration [1][5]. Intracellular β-OHB is oxidized by mitochondrial BDH1 to acetoacetate, converting NAD+ to NADH. SCOT transfers a coenzyme A moiety from succinyl-CoA to acetoacetate, generating acetoacetyl-CoA, which mitochondrial thiolase (ACAT1) cleaves into two molecules of acetyl-CoA [5].

This metabolic sequence circumvents the primary metabolic blockades caused by doxorubicin. Doxorubicin-derived reactive oxygen species inactivate the pyruvate dehydrogenase (PDH) complex through lipoate oxidation and suppress carnitine palmitoyltransferase-1B (CPT-1B) activity, limiting the entry of glucose- and lipid-derived carbons into the tricarboxylic acid (TCA) cycle [2][5]. Ketone body catabolism completely bypasses both PDH and CPT-1B. Furthermore, the conversion of β-OHB to acetyl-CoA demonstrates high thermodynamic efficiency, yielding a phosphate-to-oxygen (P/O) ratio of 2.50, which surpasses long-chain palmitate oxidation (P/O ratio of 2.33) [5]. Extracellular flux analysis reveals that β-OHB supplementation restores basal and maximal oxygen consumption rates in doxorubicin-poisoned cardiomyocytes, preserving the intracellular phosphocreatine-to-ATP ratio and preventing energetic collapse.

Mitochondrial Redox Homeostasis and Attenuation of Diastolic Stiffness

Empagliflozin-driven ketone utilization restores the mitochondrial redox state, normalizing the intramitochondrial NADH/NAD+ and NADPH/NADP+ pools required to regenerate reduced glutathione via glutathione reductase [4][6]. Reduced oxidative stress suppresses calcium/calmodulin-dependent protein kinase II (CaMKII) auto-phosphorylation at Thr286/Thr287, preventing pathological phosphorylation of RyR2 at Ser2814 that causes diastolic calcium leakage [6]. Concurrently, uncoupling of SERCA2a from its endogenous inhibitor phospholamban (PLN) is restored via normal protein kinase A-mediated phosphorylation at Ser16, accelerating cytosolic calcium clearance during diastole [4][7].

At the sarcomeric level, energetic rescue preserves protein kinase G and protein kinase A signaling, maintaining phosphorylation of the spring-like N2B isoform of titin at specific serines (Ser4010, Ser4099) within the PEVK and elastic domains [7]. This prevents the passive myofibrillar tension and sarcomeric stiffening characteristic of anthracycline cardiomyopathy. In non-diabetic rodent cohorts treated with doxorubicin, empagliflozin administration preserves the echocardiographic early-to-late diastolic mitral inflow velocity ratio (E/A) and decreases the early filling to early diastolic mitral annular velocity ratio (E/e') [4]. Left ventricular end-diastolic pressure (LVEDP) drops from pathological values exceeding 18 mmHg down to 6–8 mmHg [6]. Histological analysis reveals marked attenuation of Sirius Red-positive interstitial collagen accumulation, while cardiac expression of the inflammatory drivers MyD88, NLRP3, interleukin-1β (IL-1β), and interleukin-6 (IL-6) decreases by 35% to 54% [4][7]. TUNEL staining shows a greater than 60% reduction in apoptotic cardiomyocyte nuclei, confirming the preservation of cardiac architectural integrity.

Translational Preservation of Doxorubicin Antineoplastic Efficacy in Syngeneic Models

A central translational concern in cardioprotection is whether systemic metabolic interventions impede the antineoplastic efficacy of anthracyclines. Co-administration of empagliflozin was investigated in immunocompetent murine oncology models, including syngeneic 4T1 mammary carcinoma and B16-F10 melanoma [1][5]. Doxorubicin monotherapy (cumulative dose 15 mg/kg) achieved 65% to 75% tumor growth inhibition (TGI). Concurrent administration of empagliflozin (20 mg/kg daily) yielded no reduction in TGI, demonstrating equivalent tumor regression trajectories [5][7].

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) measurements confirm that intratumoral doxorubicin concentrations and downstream doxorubicinol metabolite levels are unaltered by SGLT2 inhibition, indicating that renal excretion and systemic pharmacokinetic distribution remain constant [1]. The selective protection observed in cardiomyocytes stems from fundamental differences in metabolic flexibility. Malignant cells, including 4T1 mammary carcinoma cells, maintain high rates of aerobic glycolysis (the Warburg effect) and frequently exhibit transcriptional repression or epigenetic silencing of SCOT (OXCT1) and BDH1 [5]. Consequently, these malignant lines cannot metabolize circulating β-OHB to compensate for doxorubicin-induced stress. Furthermore, in female Yorkshire sow models, high-dose empagliflozin preserved left ventricular ejection fraction and complex I respiratory chain function during multi-cycle doxorubicin infusions without triggering systemic metabolic derangements [5]. SGLT2 inhibition uncouples cardiomyocyte toxicity from antineoplastic potency, providing an empirical framework for oncologic cardioprotection without compromising therapeutic response.

Table 1. Comparative Pharmacological, Energetic, and Hemodynamic Benchmarks Across Experimental Conditions

Assay / Physiological ParameterVehicle Control BaselineDoxorubicin Monotherapy (15 mg/kg)Doxorubicin + EmpagliflozinTranslational Significance
Cardiomyocyte Oxygen Consumption (OCR, pmol/s/mg)8,450 ± 6204,200 ± 4107,940 ± 580Empagliflozin restores mitochondrial electron transport chain reserve capacity
Circulating Serum β-OHB (mM)0.15 ± 0.030.12 ± 0.020.88 ± 0.11Renal SGLT2 blockade elevates physiological ketone substrates for cardiac rescue
Myocardial Xanthine Oxidase (mU/mg protein)2.1 ± 1.218.5 ± 1.87.3 ± 2.5Mitigation of purine degradation-associated superoxide free radical production
E/e' Ratio (Diastolic Filling Pressure Index)14.2 ± 1.126.8 ± 2.416.5 ± 1.4Preservation of left ventricular compliance and attenuation of diastolic stiffness
Intercellular Fibrosis (% Area Sirius Red)1.8 ± 0.4%11.4 ± 1.6%4.2 ± 0.8%Significant reduction in reactive myofibrillar collagen deposition
Tumor Growth Inhibition (TGI % in 4T1 Murine Model)0.0%71.5 ± 4.2%73.1 ± 3.9%Confirmation that SGLT2 inhibition preserves antineoplastic efficacy

Note: All physiological values compiled from standardized preclinical murine and translational models of anthracycline exposure.

PRECLINICAL INVESTIGATION Q&A

Frequently Asked Questions

Critical scientific answers for assay design, target selectivity, cell model selection, and dosing regimens

What is the significance of Topoisomerase IIβ Trapping and Mitochondrial Energetic Arrest in Anthracycline Cardiotoxicity?Mechanism of Action

Anthracycline-induced cardiotoxicity restricts the clinical utility of doxorubicin in curative oncology regimens. While the antineoplastic action of doxorubicin depends on topoisomerase IIα poisoning in rapidly.

What is the significance of Systemic Ketogenesis Induction via Renal SGLT2 Blockade by Empagliflozin?Pharmacological Potency

Pharmacological inhibition of the sodium-glucose cotransporter 2 (SGLT2, encoded by SLC5A2) in the S1/S2 segments of the renal proximal convoluted tubule prevents the reabsorption of.

References

  1. [1]. Goje I, et al. International Journal of Molecular Sciences. 2026;27(7):3090. [IF: 4.9]
  2. [2]. Oh C, et al. Korean Circulation Journal. 2019;49(12):1183. [IF: 2.322]
  3. [3]. Azcona JA, et al. Molecular Imaging and Biology. 2025;27(1):109-119. [IF: 2.5]
  4. [4]. Quagliariello V, et al. Cardiovascular Diabetology. 2021;20(1). [IF: 8.949]
  5. [5]. Medina-Hernández D, et al. JACC: CardioOncology. 2025;7(2):171-184.
  6. [6]. Ulusan S, et al. The Anatolian Journal of Cardiology. 2023;339-347. [IF: 1.4]
  7. [7]. Rozovsky T, et al. Biomedicines. 2026;14(4):903. [IF: 3.9]